Skip to main content
BMC Cancer logoLink to BMC Cancer
. 2023 Jul 7;23:636. doi: 10.1186/s12885-023-11135-3

Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Yu-Yin Xu 1,2,#, Li Chen 1,✉,#, Gui-Lan Wang 1, Jia-Ming Zhou 1, Yi-Xin Zhang 3, Yin-Ze Wei 3, Yuan-Yuan Zhu 4, Jing Qin 1
PMCID: PMC10326930  PMID: 37420163

Retraction Note: BMC Cancer 13, 527 (2013)

10.1186/1471-2407-13-527

The Editor has retracted this article because it appears that some of the text and figures have been previously published by some of the same authors. Specifically:

  • there is substantial text overlap with results section in [1]

  • Figure 2B appears to present the same data as Fig. 1C in [1]

  • It appears the same FACS plots have been presented in Fig. 3B (for srfn, poly (I:C) and control) as in Fig. 4A in [1]

  • Figure 3C (sifn and Poly(I:C) ) and 3D appear to show the same images as those published previously in [1] in Fig. 3A

Author Yu-Yin Xu does not agree to this retraction. None of the other authors have responded to any correspondence from the editor or publisher about this retraction

Footnotes

The online version of the original article can be found at 10.1186/1471-2407-13-527

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Equal contributors.

Contributor Information

Li Chen, Email: bl1@ntu.edu.cn.

Jing Qin, Email: bl1@ntu.edu.cn.

References

  • 1.Chen, L., Xu, Y., Zhou, J., Wu, Y., E, Q., Zhu, Y. “TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells”. Oncology Reports 28.1 (2012): 200–206. [DOI] [PubMed]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES